Exact Mass: 720.4118

Exact Mass Matches: 720.4118

Found 82 metabolites which its exact mass value is equals to given mass value 720.4118, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

PA(13:0/6 keto-PGF1alpha)

[(2R)-2-({7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]-6-oxoheptanoyl}oxy)-3-(tridecanoyloxy)propoxy]phosphonic acid

C36H65O12P (720.4213)


PA(13:0/6 keto-PGF1alpha) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(13:0/6 keto-PGF1alpha), in particular, consists of one chain of one tridecanoyl at the C-1 position and one chain of 6-Keto-prostaglandin F1alpha at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(6 keto-PGF1alpha/13:0)

[(2R)-3-({7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]-6-oxoheptanoyl}oxy)-2-(tridecanoyloxy)propoxy]phosphonic acid

C36H65O12P (720.4213)


PA(6 keto-PGF1alpha/13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(6 keto-PGF1alpha/13:0), in particular, consists of one chain of one 6-Keto-prostaglandin F1alpha at the C-1 position and one chain of tridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(13:0/TXB2)

[(2R)-2-{[(5Z)-7-[(2R,3S,4S)-4,6-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]oxan-3-yl]hept-5-enoyl]oxy}-3-(tridecanoyloxy)propoxy]phosphonic acid

C36H65O12P (720.4213)


PA(13:0/TXB2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(13:0/TXB2), in particular, consists of one chain of one tridecanoyl at the C-1 position and one chain of Thromboxane B2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(TXB2/13:0)

[(2R)-3-{[(5Z)-7-[(2R,3S,4S)-4,6-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]oxan-3-yl]hept-5-enoyl]oxy}-2-(tridecanoyloxy)propoxy]phosphonic acid

C36H65O12P (720.4213)


PA(TXB2/13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(TXB2/13:0), in particular, consists of one chain of one Thromboxane B2 at the C-1 position and one chain of tridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(a-13:0/6 keto-PGF1alpha)

[(2R)-2-({7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]-6-oxoheptanoyl}oxy)-3-[(10-methyldodecanoyl)oxy]propoxy]phosphonic acid

C36H65O12P (720.4213)


PA(a-13:0/6 keto-PGF1alpha) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(a-13:0/6 keto-PGF1alpha), in particular, consists of one chain of one 10-methyldodecanoyl at the C-1 position and one chain of 6-Keto-prostaglandin F1alpha at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(6 keto-PGF1alpha/a-13:0)

[(2R)-3-({7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]-6-oxoheptanoyl}oxy)-2-[(10-methyldodecanoyl)oxy]propoxy]phosphonic acid

C36H65O12P (720.4213)


PA(6 keto-PGF1alpha/a-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(6 keto-PGF1alpha/a-13:0), in particular, consists of one chain of one 6-Keto-prostaglandin F1alpha at the C-1 position and one chain of 10-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(a-13:0/TXB2)

[(2R)-2-{[(5Z)-7-[(2R,3S,4S)-4,6-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]oxan-3-yl]hept-5-enoyl]oxy}-3-[(10-methyldodecanoyl)oxy]propoxy]phosphonic acid

C36H65O12P (720.4213)


PA(a-13:0/TXB2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(a-13:0/TXB2), in particular, consists of one chain of one 10-methyldodecanoyl at the C-1 position and one chain of Thromboxane B2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(TXB2/a-13:0)

[(2R)-3-{[(5Z)-7-[(2R,3S,4S)-4,6-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]oxan-3-yl]hept-5-enoyl]oxy}-2-[(10-methyldodecanoyl)oxy]propoxy]phosphonic acid

C36H65O12P (720.4213)


PA(TXB2/a-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(TXB2/a-13:0), in particular, consists of one chain of one Thromboxane B2 at the C-1 position and one chain of 10-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-13:0/6 keto-PGF1alpha)

[(2R)-2-({7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]-6-oxoheptanoyl}oxy)-3-[(11-methyldodecanoyl)oxy]propoxy]phosphonic acid

C36H65O12P (720.4213)


PA(i-13:0/6 keto-PGF1alpha) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-13:0/6 keto-PGF1alpha), in particular, consists of one chain of one 11-methyldodecanoyl at the C-1 position and one chain of 6-Keto-prostaglandin F1alpha at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(6 keto-PGF1alpha/i-13:0)

[(2R)-3-({7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]-6-oxoheptanoyl}oxy)-2-[(11-methyldodecanoyl)oxy]propoxy]phosphonic acid

C36H65O12P (720.4213)


PA(6 keto-PGF1alpha/i-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(6 keto-PGF1alpha/i-13:0), in particular, consists of one chain of one 6-Keto-prostaglandin F1alpha at the C-1 position and one chain of 11-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-13:0/TXB2)

[(2R)-2-{[(5Z)-7-[(2R,3S,4S)-4,6-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]oxan-3-yl]hept-5-enoyl]oxy}-3-[(11-methyldodecanoyl)oxy]propoxy]phosphonic acid

C36H65O12P (720.4213)


PA(i-13:0/TXB2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-13:0/TXB2), in particular, consists of one chain of one 11-methyldodecanoyl at the C-1 position and one chain of Thromboxane B2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(TXB2/i-13:0)

[(2R)-3-{[(5Z)-7-[(2R,3S,4S)-4,6-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]oxan-3-yl]hept-5-enoyl]oxy}-2-[(11-methyldodecanoyl)oxy]propoxy]phosphonic acid

C36H65O12P (720.4213)


PA(TXB2/i-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(TXB2/i-13:0), in particular, consists of one chain of one Thromboxane B2 at the C-1 position and one chain of 11-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   
   

Candicanoside A

Candicanoside A

C39H60O12 (720.4085)


   

Bafilomycin C1

Bafilomycin C1

C39H60O12 (720.4085)


   

Hebelomic acid B

Hebelomic acid B

C39H60O12 (720.4085)


   

12beta,25-O-diacetylcimigenol-3-O-beta-D-xylopyranoside|25-O-acetyl-12beta-acetoxycimigenol-3-O-beta-D-xylopyranoside

12beta,25-O-diacetylcimigenol-3-O-beta-D-xylopyranoside|25-O-acetyl-12beta-acetoxycimigenol-3-O-beta-D-xylopyranoside

C39H60O12 (720.4085)


   

3alpha-Angeloyloxy-2beta,15-dihydroxy-ent-labd-7-ene-2-O-alpha-rhamnopyranoside tetraacetate

3alpha-Angeloyloxy-2beta,15-dihydroxy-ent-labd-7-ene-2-O-alpha-rhamnopyranoside tetraacetate

C39H60O12 (720.4085)


   

fruticoside H|spirosta-5,25(27)-diene-1beta,3beta-diol-1-O-alpha-L-rhamnopyranosyl-(1?2)-beta-D-fucopyranoside

fruticoside H|spirosta-5,25(27)-diene-1beta,3beta-diol-1-O-alpha-L-rhamnopyranosyl-(1?2)-beta-D-fucopyranoside

C39H60O12 (720.4085)


   

cayaponoside A3

cayaponoside A3

C39H60O12 (720.4085)


   

beta-D-glucopyranosyl (3beta)-29-acetoxy-3-hydroxy-23-methoxy-23-oxoolean-12-en-28-oate|kalidiumoside B

beta-D-glucopyranosyl (3beta)-29-acetoxy-3-hydroxy-23-methoxy-23-oxoolean-12-en-28-oate|kalidiumoside B

C39H60O12 (720.4085)


   

OHODA-PG

1-(9Z-octadecenoyl)-2-(9-hydroxy-12-oxo-10E-dodecenoyl)-sn-glycero-3-phospho-(1-sn-glycerol)

C36H65O12P (720.4213)


   

23R,24S-diacetoxy-3beta,15alpha,25-trihydroxy-cycloart-7-en-16-one-3-O-beta-D-xylopyranoside

23R,24S-diacetoxy-3beta,15alpha,25-trihydroxy-cyclo-lanost-7-en-16one-3- O-beta-D-xylopyranoside

C39H60O12 (720.4085)


   

Tirilazad mesylate

Tirilazad mesylate

C39H56N6O5S (720.4033)


D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents D020011 - Protective Agents > D000975 - Antioxidants

   

PA(a-13:0/TXB2)

PA(a-13:0/TXB2)

C36H65O12P (720.4213)


   

PA(TXB2/a-13:0)

PA(TXB2/a-13:0)

C36H65O12P (720.4213)


   

PA(i-13:0/TXB2)

PA(i-13:0/TXB2)

C36H65O12P (720.4213)


   

PA(TXB2/i-13:0)

PA(TXB2/i-13:0)

C36H65O12P (720.4213)


   

PA(13:0/6 keto-PGF1alpha)

PA(13:0/6 keto-PGF1alpha)

C36H65O12P (720.4213)


   

PA(6 keto-PGF1alpha/13:0)

PA(6 keto-PGF1alpha/13:0)

C36H65O12P (720.4213)


   
   
   

PA(a-13:0/6 keto-PGF1alpha)

PA(a-13:0/6 keto-PGF1alpha)

C36H65O12P (720.4213)


   

PA(6 keto-PGF1alpha/a-13:0)

PA(6 keto-PGF1alpha/a-13:0)

C36H65O12P (720.4213)


   

PA(i-13:0/6 keto-PGF1alpha)

PA(i-13:0/6 keto-PGF1alpha)

C36H65O12P (720.4213)


   

PA(6 keto-PGF1alpha/i-13:0)

PA(6 keto-PGF1alpha/i-13:0)

C36H65O12P (720.4213)


   

Smgdg O-9:0_18:3

Smgdg O-9:0_18:3

C36H64O12S (720.4118)


   

Smgdg O-22:3_5:0

Smgdg O-22:3_5:0

C36H64O12S (720.4118)


   

Smgdg O-18:3_9:0

Smgdg O-18:3_9:0

C36H64O12S (720.4118)


   

Smgdg O-20:3_7:0

Smgdg O-20:3_7:0

C36H64O12S (720.4118)


   

Smgdg O-24:3_3:0

Smgdg O-24:3_3:0

C36H64O12S (720.4118)


   

Smgdg O-11:0_16:3

Smgdg O-11:0_16:3

C36H64O12S (720.4118)


   

Smgdg O-16:3_11:0

Smgdg O-16:3_11:0

C36H64O12S (720.4118)


   

[1-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] undecanoate

[1-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] undecanoate

C36H65O12P (720.4213)


   

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-undecoxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-undecoxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

C36H65O12P (720.4213)


   

[3,4,5-trihydroxy-6-[2-[(Z)-tetradec-9-enoyl]oxy-3-[(Z)-tridec-9-enoyl]oxypropoxy]oxan-2-yl]methanesulfonic acid

[3,4,5-trihydroxy-6-[2-[(Z)-tetradec-9-enoyl]oxy-3-[(Z)-tridec-9-enoyl]oxypropoxy]oxan-2-yl]methanesulfonic acid

C36H64O12S (720.4118)


   

[(2R,3R,6R)-6-[(2S)-2-decanoyloxy-3-[(9E,12E)-heptadeca-9,12-dienoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

[(2R,3R,6R)-6-[(2S)-2-decanoyloxy-3-[(9E,12E)-heptadeca-9,12-dienoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C36H64O12S (720.4118)


   

[(2S,3S,6S)-6-[(2S)-3-decanoyloxy-2-[(9E,12E)-heptadeca-9,12-dienoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

[(2S,3S,6S)-6-[(2S)-3-decanoyloxy-2-[(9E,12E)-heptadeca-9,12-dienoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C36H64O12S (720.4118)


   

[(2S,3S,6S)-6-[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-undecanoyloxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

[(2S,3S,6S)-6-[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-undecanoyloxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C36H64O12S (720.4118)


   
   
   
   
   
   

PG P-18:0/12:3;O3

PG P-18:0/12:3;O3

C36H65O12P (720.4213)


   

PG P-18:1/12:2;O3

PG P-18:1/12:2;O3

C36H65O12P (720.4213)


   

PG 18:0/12:3;O2

PG 18:0/12:3;O2

C36H65O12P (720.4213)


   

PG 18:1/12:2;O2

PG 18:1/12:2;O2

C36H65O12P (720.4213)


   
   
   
   

(2s,3s,4as,5r,8as)-5-[(3s)-5-(acetyloxy)-3-methylpentyl]-1,1,4a,6-tetramethyl-3-{[(2r,3r,4r,5s,6s)-3,4,5-tris(acetyloxy)-6-methyloxan-2-yl]oxy}-2,3,4,5,8,8a-hexahydronaphthalen-2-yl (2z)-2-methylbut-2-enoate

(2s,3s,4as,5r,8as)-5-[(3s)-5-(acetyloxy)-3-methylpentyl]-1,1,4a,6-tetramethyl-3-{[(2r,3r,4r,5s,6s)-3,4,5-tris(acetyloxy)-6-methyloxan-2-yl]oxy}-2,3,4,5,8,8a-hexahydronaphthalen-2-yl (2z)-2-methylbut-2-enoate

C39H60O12 (720.4085)


   

(2s)-4-{[(1r,3as,5ar,7r,8r,9as,11s,11ar)-7,11-bis(acetyloxy)-1-[(2s,3r,6s)-2-hydroxy-6-(2-hydroxypropan-2-yl)oxan-3-yl]-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-8-yl]oxy}-2-hydroxy-2-methyl-4-oxobutanoic acid

(2s)-4-{[(1r,3as,5ar,7r,8r,9as,11s,11ar)-7,11-bis(acetyloxy)-1-[(2s,3r,6s)-2-hydroxy-6-(2-hydroxypropan-2-yl)oxan-3-yl]-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-8-yl]oxy}-2-hydroxy-2-methyl-4-oxobutanoic acid

C39H60O12 (720.4085)


   

(4as,6as,6br,8ar,9r,10s,12ar,12br,14br)-10-{[(2r,3r,4s,5s)-4,5-dihydroxy-3-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}oxan-2-yl]oxy}-9-(hydroxymethyl)-6a,6b,9,12a-tetramethyl-2-methylidene-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

(4as,6as,6br,8ar,9r,10s,12ar,12br,14br)-10-{[(2r,3r,4s,5s)-4,5-dihydroxy-3-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}oxan-2-yl]oxy}-9-(hydroxymethyl)-6a,6b,9,12a-tetramethyl-2-methylidene-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

C39H60O12 (720.4085)


   

18,24:20,24-diepoxycycloartane-3,15,16,25-tetrol; (3β,15β,16β,20s,24r)-form,3-o-beta-d-xylopyranoside,15,16-di-ac

NA

C39H60O12 (720.4085)


{"Ingredient_id": "HBIN002079","Ingredient_name": "18,24:20,24-diepoxycycloartane-3,15,16,25-tetrol; (3\u03b2,15\u03b2,16\u03b2,20s,24r)-form,3-o-beta-d-xylopyranoside,15,16-di-ac","Alias": "NA","Ingredient_formula": "C39H60O12","Ingredient_Smile": "NA","Ingredient_weight": "0","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "9259","PubChem_id": "NA","DrugBank_id": "NA"}

   

beesioside i

NA

C39H60O12 (720.4085)


{"Ingredient_id": "HBIN017683","Ingredient_name": "beesioside i","Alias": "NA","Ingredient_formula": "C39H60O12","Ingredient_Smile": "CC(=O)OC1C2C3(CCC(O3)(OCC24CCC56CC57CCC(C(C7CCC6C4(C1OC(=O)C)C)(C)C)OC8C(C(C(CO8)O)O)O)C(C)(C)O)C","Ingredient_weight": "720.9 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "2200","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "15908521","DrugBank_id": "NA"}

   

(3as,7as)-n-(5-carbamimidamido-1-hydroxypentan-2-yl)-6-{[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}-1-[(2s)-2-[(1-hydroxyhexylidene)amino]-3-(4-hydroxyphenyl)propanoyl]-octahydroindole-2-carboximidic acid

(3as,7as)-n-(5-carbamimidamido-1-hydroxypentan-2-yl)-6-{[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}-1-[(2s)-2-[(1-hydroxyhexylidene)amino]-3-(4-hydroxyphenyl)propanoyl]-octahydroindole-2-carboximidic acid

C35H56N6O10 (720.4058)


   

10-({4,5-dihydroxy-3-[(3,4,5-trihydroxyoxan-2-yl)oxy]oxan-2-yl}oxy)-9-(hydroxymethyl)-6a,6b,9,12a-tetramethyl-2-methylidene-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

10-({4,5-dihydroxy-3-[(3,4,5-trihydroxyoxan-2-yl)oxy]oxan-2-yl}oxy)-9-(hydroxymethyl)-6a,6b,9,12a-tetramethyl-2-methylidene-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

C39H60O12 (720.4085)


   

2-[(2-{[12,21-dimethyl-20-(2-methylprop-1-en-1-yl)-18,23-dioxahexacyclo[17.3.1.0³,¹⁶.0⁴,¹³.0⁷,¹².0¹⁶,²²]tricos-6-en-9-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl)oxy]-6-methyloxane-3,4,5-triol

2-[(2-{[12,21-dimethyl-20-(2-methylprop-1-en-1-yl)-18,23-dioxahexacyclo[17.3.1.0³,¹⁶.0⁴,¹³.0⁷,¹².0¹⁶,²²]tricos-6-en-9-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl)oxy]-6-methyloxane-3,4,5-triol

C39H60O12 (720.4085)


   

(2e)-4-{[(2r,4s,5r,6s)-4-hydroxy-2-[(2s,3r,4s)-3-hydroxy-4-[(3s,4e,6e,9s,10r,11r,12e,14e)-10-hydroxy-3,15-dimethoxy-7,9,11,13-tetramethyl-16-oxo-1-oxacyclohexadeca-4,6,12,14-tetraen-2-yl]pentan-2-yl]-6-isopropyl-5-methyloxan-2-yl]oxy}-4-oxobut-2-enoic acid

(2e)-4-{[(2r,4s,5r,6s)-4-hydroxy-2-[(2s,3r,4s)-3-hydroxy-4-[(3s,4e,6e,9s,10r,11r,12e,14e)-10-hydroxy-3,15-dimethoxy-7,9,11,13-tetramethyl-16-oxo-1-oxacyclohexadeca-4,6,12,14-tetraen-2-yl]pentan-2-yl]-6-isopropyl-5-methyloxan-2-yl]oxy}-4-oxobut-2-enoic acid

C39H60O12 (720.4085)


   

5-[5-(acetyloxy)-3-methylpentyl]-1,1,4a,6-tetramethyl-3-{[3,4,5-tris(acetyloxy)-6-methyloxan-2-yl]oxy}-2,3,4,5,8,8a-hexahydronaphthalen-2-yl 2-methylbut-2-enoate

5-[5-(acetyloxy)-3-methylpentyl]-1,1,4a,6-tetramethyl-3-{[3,4,5-tris(acetyloxy)-6-methyloxan-2-yl]oxy}-2,3,4,5,8,8a-hexahydronaphthalen-2-yl 2-methylbut-2-enoate

C39H60O12 (720.4085)


   

(4ar,6ar,6bs,8as,9s,10r,12as,12bs,14br)-10-{[(2r,3s,4r,5s)-4,5-dihydroxy-3-{[(2r,3s,4r,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}oxan-2-yl]oxy}-9-(hydroxymethyl)-6a,6b,9,12a-tetramethyl-2-methylidene-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

(4ar,6ar,6bs,8as,9s,10r,12as,12bs,14br)-10-{[(2r,3s,4r,5s)-4,5-dihydroxy-3-{[(2r,3s,4r,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}oxan-2-yl]oxy}-9-(hydroxymethyl)-6a,6b,9,12a-tetramethyl-2-methylidene-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

C39H60O12 (720.4085)


   

5-({5-[(1,5-dihydroxy-3-methylpent-2-en-1-ylidene)amino]-2-[(1-hydroxyethylidene)amino]pentanoyl}oxy)-n-[3-(5-{3-[(1,5-dihydroxy-3-methylpent-2-en-1-ylidene)amino]propyl}-3,6-dihydroxy-2,5-dihydropyrazin-2-yl)propyl]-3-methylpent-2-enimidic acid

5-({5-[(1,5-dihydroxy-3-methylpent-2-en-1-ylidene)amino]-2-[(1-hydroxyethylidene)amino]pentanoyl}oxy)-n-[3-(5-{3-[(1,5-dihydroxy-3-methylpent-2-en-1-ylidene)amino]propyl}-3,6-dihydroxy-2,5-dihydropyrazin-2-yl)propyl]-3-methylpent-2-enimidic acid

C35H56N6O10 (720.4058)


   

(2e)-4-{[(2r,4r,5s,6r)-2-hydroxy-2-[(2s,3r,4s)-3-hydroxy-4-[(3s,4z,6e,9s,10s,11r,12e,14z)-10-hydroxy-3,15-dimethoxy-7,9,11,13-tetramethyl-16-oxo-1-oxacyclohexadeca-4,6,12,14-tetraen-2-yl]pentan-2-yl]-6-isopropyl-5-methyloxan-4-yl]oxy}-4-oxobut-2-enoic acid

(2e)-4-{[(2r,4r,5s,6r)-2-hydroxy-2-[(2s,3r,4s)-3-hydroxy-4-[(3s,4z,6e,9s,10s,11r,12e,14z)-10-hydroxy-3,15-dimethoxy-7,9,11,13-tetramethyl-16-oxo-1-oxacyclohexadeca-4,6,12,14-tetraen-2-yl]pentan-2-yl]-6-isopropyl-5-methyloxan-4-yl]oxy}-4-oxobut-2-enoic acid

C39H60O12 (720.4085)


   

(2s,3r,4r,5r,6s)-2-{[(2r,3r,4s,5s,6r)-2-{[(1s,3s,4r,9s,12r,13s,16r,19s,20s,21s,22r)-12,21-dimethyl-20-(2-methylprop-1-en-1-yl)-18,23-dioxahexacyclo[17.3.1.0³,¹⁶.0⁴,¹³.0⁷,¹².0¹⁶,²²]tricos-6-en-9-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy}-6-methyloxane-3,4,5-triol

(2s,3r,4r,5r,6s)-2-{[(2r,3r,4s,5s,6r)-2-{[(1s,3s,4r,9s,12r,13s,16r,19s,20s,21s,22r)-12,21-dimethyl-20-(2-methylprop-1-en-1-yl)-18,23-dioxahexacyclo[17.3.1.0³,¹⁶.0⁴,¹³.0⁷,¹².0¹⁶,²²]tricos-6-en-9-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy}-6-methyloxane-3,4,5-triol

C39H60O12 (720.4085)


   

(2e)-4-[(2-hydroxy-2-{3-hydroxy-4-[(4e,6e,12e,14z)-10-hydroxy-3,15-dimethoxy-7,9,11,13-tetramethyl-16-oxo-1-oxacyclohexadeca-4,6,12,14-tetraen-2-yl]pentan-2-yl}-6-isopropyl-5-methyloxan-4-yl)oxy]-4-oxobut-2-enoic acid

(2e)-4-[(2-hydroxy-2-{3-hydroxy-4-[(4e,6e,12e,14z)-10-hydroxy-3,15-dimethoxy-7,9,11,13-tetramethyl-16-oxo-1-oxacyclohexadeca-4,6,12,14-tetraen-2-yl]pentan-2-yl}-6-isopropyl-5-methyloxan-4-yl)oxy]-4-oxobut-2-enoic acid

C39H60O12 (720.4085)


   

(2e)-5-{[(2s)-5-{[(2e)-1,5-dihydroxy-3-methylpent-2-en-1-ylidene]amino}-2-[(1-hydroxyethylidene)amino]pentanoyl]oxy}-n-{3-[(2s,5s)-5-(3-{[(2e)-1,5-dihydroxy-3-methylpent-2-en-1-ylidene]amino}propyl)-3,6-dihydroxy-2,5-dihydropyrazin-2-yl]propyl}-3-methylpent-2-enimidic acid

(2e)-5-{[(2s)-5-{[(2e)-1,5-dihydroxy-3-methylpent-2-en-1-ylidene]amino}-2-[(1-hydroxyethylidene)amino]pentanoyl]oxy}-n-{3-[(2s,5s)-5-(3-{[(2e)-1,5-dihydroxy-3-methylpent-2-en-1-ylidene]amino}propyl)-3,6-dihydroxy-2,5-dihydropyrazin-2-yl]propyl}-3-methylpent-2-enimidic acid

C35H56N6O10 (720.4058)


   

(2r,3r,4s,5s,6r,9r,11s,14r,16s,19s,22s)-4-(acetyloxy)-22-(2-hydroxypropan-2-yl)-1,5,10,10-tetramethyl-11-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-21,25-dioxaheptacyclo[20.2.1.0²,¹⁹.0⁵,¹⁹.0⁶,¹⁶.0⁹,¹⁴.0¹⁴,¹⁶]pentacosan-3-yl acetate

(2r,3r,4s,5s,6r,9r,11s,14r,16s,19s,22s)-4-(acetyloxy)-22-(2-hydroxypropan-2-yl)-1,5,10,10-tetramethyl-11-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-21,25-dioxaheptacyclo[20.2.1.0²,¹⁹.0⁵,¹⁹.0⁶,¹⁶.0⁹,¹⁴.0¹⁴,¹⁶]pentacosan-3-yl acetate

C39H60O12 (720.4085)


   

(1s,2r,3r,4s,5s,6r,9r,11s,14r,16s,19s,22s)-4-(acetyloxy)-22-(2-hydroxypropan-2-yl)-1,5,10,10-tetramethyl-11-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-21,25-dioxaheptacyclo[20.2.1.0²,¹⁹.0⁵,¹⁹.0⁶,¹⁶.0⁹,¹⁴.0¹⁴,¹⁶]pentacosan-3-yl acetate

(1s,2r,3r,4s,5s,6r,9r,11s,14r,16s,19s,22s)-4-(acetyloxy)-22-(2-hydroxypropan-2-yl)-1,5,10,10-tetramethyl-11-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-21,25-dioxaheptacyclo[20.2.1.0²,¹⁹.0⁵,¹⁹.0⁶,¹⁶.0⁹,¹⁴.0¹⁴,¹⁶]pentacosan-3-yl acetate

C39H60O12 (720.4085)


   

(2s,3s,4as,5r,8as)-5-[(3s)-5-(acetyloxy)-3-methylpentyl]-1,1,4a,6-tetramethyl-3-{[(2r,3s,4r,5r,6s)-3,4,5-tris(acetyloxy)-6-methyloxan-2-yl]oxy}-2,3,4,5,8,8a-hexahydronaphthalen-2-yl (2z)-2-methylbut-2-enoate

(2s,3s,4as,5r,8as)-5-[(3s)-5-(acetyloxy)-3-methylpentyl]-1,1,4a,6-tetramethyl-3-{[(2r,3s,4r,5r,6s)-3,4,5-tris(acetyloxy)-6-methyloxan-2-yl]oxy}-2,3,4,5,8,8a-hexahydronaphthalen-2-yl (2z)-2-methylbut-2-enoate

C39H60O12 (720.4085)


   

(2s,3as,7as)-n-(5-carbamimidamido-1-hydroxypentan-2-yl)-6-{[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}-1-[(2s)-2-[(1-hydroxyhexylidene)amino]-3-(4-hydroxyphenyl)propanoyl]-octahydroindole-2-carboximidic acid

(2s,3as,7as)-n-(5-carbamimidamido-1-hydroxypentan-2-yl)-6-{[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}-1-[(2s)-2-[(1-hydroxyhexylidene)amino]-3-(4-hydroxyphenyl)propanoyl]-octahydroindole-2-carboximidic acid

C35H56N6O10 (720.4058)